HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

Similar documents
HIV Drugs and the HIV Lifecycle

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

Antiretroviral Dosing in Renal Impairment

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

Antiretrovial Crushable/Liquid Formulation Chart

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

ANTIRETROVIRAL TREATMENTS (Part 1of

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

HIV medications HIV medication and schedule plan

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

HIV Infection & AIDS in Low- and Middle-Income Countries

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection


Nobel /03/28. HIV virus and infected CD4+ T cells

Nothing to disclose.

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

HIV Management Update 2015

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

October 26-28: Training Day 1

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

Appropriate Use & Safety Edits

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP

Drug Treatment Program Update

The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease

continuing education for pharmacists

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

Midwestern Underwriting Conference 2016

treatment passport 1

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners

Simplifying HIV Treatment Now and in the Future

Selecting an Initial Antiretroviral Therapy (ART) Regimen

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

Approach for the Newly Diagnosed HIV Positive Patient

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

Human Immunodeficiency Virus (HIV)

Medication Errors Focus on the HIV-Infected Patient

Matters of the HAART: An Update on Current Treatment Options for HIV

Antiretroviral Pregnancy Registry

World AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary

ABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

May 2016 P & T Updates

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

Industry Data Request

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

Addressing Pediatric Needs of the Most Neglected: next steps

Exploring HIV in 2017: What a pharmacist needs to know

Jonathan Cohn MD Wayne State University July 24,

Sculpting a Better Regimen: The ART of HIV Medications

Human Immunodeficiency Virus Infection A Modern Day Epidemic

New Frontiers for Treatment Strategies for HIV Care

Genotyping and Drug Resistance in Clinical Practice. Case Studies

Fundamentals of Antiretroviral Therapy

Industry Request Integrase Inhibitors

TRANSPARENCY COMMITTEE

NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

HIV epidemiology since HIV in the United States. HIV Transmission

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary

HIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

The ART of Managing Drug-Drug Interactions in Patients with HIV

PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY

Didactic Series. Switching Regimens in the Setting of Virologic Suppression

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters

HIV Treatment Guidelines

Quick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents

HIV/AIDS Update 2007

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

30 Years of HIV: An Update on Treatment Guidelines and Beyond

ORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS

P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS

C.W. Shafer, MD HIV Specialist, AAHIVM Sioux Falls Family Medicine Residency Falls Community Health

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

Outline Epidemiology: Global and U.S. How are we doing in terms of goals of treatment? Updates in the fast moving field of HIV medicine EPIDEMIOLOGY

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

INDEX. indications...11 initiation of metabolic and morphologic complications

Actualización y Futuro en VIH

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014

Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians

Does tenofovir (TDF) cause liver injury?

Transcription:

HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/ rilpivirine/ alafenamide elvitegravir/ cobicistat/ abacavir/ dolutegravir/ CCR5 Inhibitor Atripla 600/200/300 mg 02300699 1 daily Complera 200/25/300 mg 02374129 1 daily Genvoya 150/150 mg/200/10 mg 02449498 1 daily Odefsey 200/25/25 mg Available in the U.S. 1 daily Stribild Triumeq 150/150 mg/200/300 mg abacavir 600mg, dolutegravir 50mg and 300mg 02397137 1 daily 02430932 1 daily maraviroc Celsentri (US: Selzentry) 150 mg and 300 mg 02299844 (150 mg) 02299852 (300 mg) 150-600 Integrase Inhibitor dolutegravir Tivicay 50 mg 02414945 50 mg daily (naïve) or BID (experienced) elvitegravir Vitekta 85 and 150 mg 02411172 (85 mg) raltegravir Isentress 400 mg raltegravir/ NRTIs: Combination Products 100 mg, 25 mg chewable 02411180 (150 mg) 02301881 Dutrebis 300 mg/150 mg Licensed but not commercially available in U.S. 85-150 mg daily 400 75-300 based on weight (pediatric) Abacavir, Kivexa (US: Epzicom) 600/300 mg 02269341 1 daily

Tenofovir disoproxil, emtricitabine Tenofovir alafenamide, emtrictabine zidovudine/ zidovudine/ / abacavir Truvada 300/200 mg 02274906 1 daily Descovy Combivir Lamivudine- Zidovudine 25/200 mg 10/200 mg 300 mg/150 mg 02454424 02454416 02239213 02375540 1 daily 1 BID Trizivir 300/150/300 mg 02244757 1 BID NRTIs (nucleos(t)ide reverse transcriptase inhibitors) abacavir Ziagen 300 mg 02240357 300 or 600 mg QD AZT, zidovudine Retrovir 300 mg 01902660 (100 mg) 300, or 200 mg TID 3TC, Zidovudine Novo-AZT 01946323 01953877 3TC 150, 300 mg 02192683 (150 mg) 02247825 (300 mg) Lamivudine 150, 300 mg 02369052 (150 mg) 02369060 (300 mg) 150 or 300 mg QD ddi, didanosine Videx 2g, 4 g bottles pediatric powder for oral solution ddi, didanosine Videx EC 125, 200, 250, 400 mg enteric coated capsules 01940635 (4g) 400 mg daily, or 200 02244596 (125 mg) 02244597 (200 mg) 02244598 (250 mg) 02244599 (400 mg) d4t, stavudine Zerit 15, 20, 30, 40 mg capsule 02216108 (30 mg); 02216116 (40 mg) 400 mg daily 30-40 FTC, Emtricitabine Emtriva 200 mg capsule 10 mg/ml oral solution Viread 300 mg 150, 200, 250 mg 40 mg/1g oral powder NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors) delavirdine Rescriptor 100 mg (200 mg in U.S.) 02272091; 02247128 Available in U.S. 200 mg once a day 300 mg once daily 02238348 400 mg TID

efavirenz Sustiva 200, 100, 50 mg capsule, 600 mg 02239886 (50 mg), 02239887 (100 mg), 02239888 (200 mg), 02246045 (600 mg) 600 mg daily etravirine Intelence 100, 200 mg (25 mg in U.S.) nevirapine Viramune Auro- Nevirapine Viramune XR 200 mg 200 mg (generic) 400 mg 02306778 (100 mg), 02375931 (200 mg) 02238748 02318601 02367289 200 200 mg daily x 14 days, then 200 mg BID 400 mg QD rilpivirine Edurant 25 mg 02370603 25 mg QD Protease Inhibitors atazanavir Reyataz 150, 200, 300 mg capsule 02248610 (150 mg); 02248611 (200 mg); 02294176 (300 mg) atazanavir/ cobicistat 400 mg QD, or 300 mg with 100 mg ritonavir QD Evotaz 300 mg/150 mg 02446731 1 daily darunavir Prezista 75, 150, 400, 600, 800 mg darunavir/ cobicistat fosamprenavir (100 mg/ml oral suspension in U.S.) 02338432 (75 mg); 02369753 (150 mg); 02324016 (400 mg); 02324024 (600 mg); 02393050 (800 mg) 600 mg plus 100 mg ritonavir BID or 800/100 mg QD for naive subjects Prezcobix 800 mg/150 mg 02426501 1 daily Telzir (US: Lexiva) 700 mg 50 mg/ml oral suspension 02261545 (700 mg), 02261553 (susp) indinavir Crixivan 200, 400 mg capsules 02229161 (200 mg); 02229196 (400 mg) 700 mg plus 100 mg ritonavir BID, or 1400 mg plus 100-200 mg ritonavir QD 800 mg q8h lopinavir/ ritonavir Kaletra 200/50 mg 100/25 mg 80mg/20 mg per ml solution 022285533 02312301 02243644 400/100 or 800/200 mg QD (naïve subjects) nelfinavir Viracept 250 mg (blue), 625 mg (white) 02238617 (250 mg); 02248761 (625 mg) 1250 or 750 mg TID ritonavir Norvir 100 mg 80 mg/ml solution saquinavir Invirase 200 mg hard gel capsule 500 mg film-coated 02229137 02357593 02229145 02216965 02279320 100-200 mg QD/BID as booster 1000 mg/100 mg rtv BID

tipranavir Aptivus 250 mg capsule 02273322 500 mg/200 mg ritonavir BID Fusion Inhibitor enfuvirtide Fuzeon 108 mg/vial (powder for injection) 02247725 90 mg SC BID Pharmacokinetic Enhancer cobicistat Tybost 150 mg 02411423 150 mg daily A. Tseng, Pharm.D., FCSHP, AAHIVP, Toronto General Hospital May 2016

DISCONTINUED HIV MEDICATIONS Generic Name Trade Name Strength DIN Usual Dosage NRTIs (nucleoside reverse transcriptase inhibitors) ddi, didanosine Videx 25, 50, 100, 150 mg ddc, zalcitabine 01940546 (100 mg) 01940554 (150 mg) D/C February 2006 Hivid 0.75 mg 01990896 (0.75 mg) D/C February 28, 2006 400 mg daily, or 200 0.75 mg TID Protease Inhibitors amprenavir Agenerase 50, 150 mg capsule 02243541 (50 mg), 02243542 (150 mg) D/C December 2006 1200 darunavir Prezista 300 mg 02284057 Replaced by 600 mg nelfinavir Viracept Oral powder 50mg/g (1g= level scoopful) 02238618 (D/C 2006) saquinavir Fortovase 200 mg soft gel capsule 02239083 lopinavir/ ritonavir (D/C 2006) Kaletra 133mg/33 mg capsule 02243643 (d/c July 11, 2008) 1200 mg TID or 1600 400/100 or 800/200 mg QD (naïve subjects)